Streetbeat News

Earnings

BCDA

BioCardia, a biotechnology company, reported ending the year 2023 with cash and cash equivalents totaling $1.1 million. This financial update provides insight into the company's liquidity and financial health as of the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 6:04 pm

TOST

Analyst ratings for Toast (NYSE:TOST) show a mix of bullish and bearish perspectives with an average 12-month price target of $22.64, up 41.5% from the previous target. Recent analyst actions include various ratings and price target adjustments, reflecting evolving market conditions and company performance. Toast, a U.S.-based restaurant technology company, has shown a revenue growth rate of 34.9% as of December 31, 2023, but faces challenges in profitability and efficiency, with a net margin of -3.47%, ROE of -3.07%, and ROA of -1.9%.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 6:01 pm

CLSK

Cleanspark (NASDAQ:CLSK), a bitcoin mining company, has received updated analyst ratings over the last three months, with a notable shift towards bullish sentiment. The average 12-month price target for CLSK has been raised to $23.67, reflecting a 47.94% increase from the previous target of $16.00. Analysts from firms like HC Wainwright & Co. and BTIG have adjusted their price targets and maintained or raised their ratings, indicating a positive outlook on the company's performance. Cleanspark's financial overview highlights significant revenue growth, a high net margin, and strong ROE and ROA, positioning it favorably in the Information Technology sector.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 6:01 pm

INMB

INmune Bio (NASDAQ:INMB) is scheduled to release its quarterly earnings report on March 28, 2024, with analysts expecting an EPS of $-0.44. The company's past earnings performance shows a mixed record of beating and missing EPS estimates, affecting its stock price. Shares of INmune Bio have seen a significant increase over the last year, trading at $11.88 as of March 26, with a 99.42% rise over the 52-week period. Investors are looking forward to not only the earnings results but also the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 6:01 pm

DLPN

Dolphin Entertainment (NASDAQ:DLPN) is scheduled to release its quarterly earnings report on March 28, 2024. Analysts predict an EPS of $0.00. The company's past performance shows a pattern of not meeting EPS estimates, with stock price reactions varying post-earnings announcement. Shares are currently trading at $1.37, reflecting a 24.32% decline over the last year. Investors are focused on the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 6:01 pm

ACNT

Ascent Industries (NASDAQ:ACNT) is scheduled to release its quarterly earnings report on March 28, 2024, with an expected EPS of $-0.08. Despite a miss in the last quarter's EPS by $1.14, the stock price increased by 4.09% the following day. Over the last year, ACNT shares have risen by 12.09%, indicating a generally positive outlook from long-term shareholders. Investors will be keenly watching for not just the earnings outcome but also the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 6:01 pm

CELH

GME

IWM

MAGS

NCNO

TLT

Wall Street saw mixed performance with tech giants slightly down, while blue chips and small caps gained. The S&P 500, Dow Jones, and Nasdaq showed varied movements. The Roundhill Magnificent Seven ETF and iShares Russell 2000 ETF experienced declines and gains respectively. Gold and the iShares 20+ Year Treasury Bond ETF rose, while Bitcoin fell. Sector-wise, utilities and real estate outperformed, whereas technology was flat. Key stock movements included nCino, GameStop, and others reacting to earnings or updates.

Portfolio Pulse from Piero Cingari

March 27, 2024 | 5:51 pm

PFE

Financial analysis reveals a bullish sentiment among big money traders on Pfizer (NYSE:PFE), with 66% of observed options trades being bullish. The analysis, based on 15 unusual trades, shows a preference for calls over puts, indicating expectations for Pfizer's stock to rise. The targeted price range for these options is between $20.0 and $50.0. Pfizer, a leading pharmaceutical company with annual sales nearing $50 billion, is currently experiencing a slight increase in stock price to $27.7, with an upcoming earnings release in 35 days.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 5:46 pm

NEE

NextEra Energy (NYSE:NEE) has seen unusual options activity indicating a mixed sentiment among big-money traders, with a bearish lean. Benzinga's options scanner revealed 11 significant trades, with a sentiment split of 45% bullish and 54% bearish. The trades suggest a price target range of $49.0 to $67.5. The current stock price is $62.16, with a recent uptick of 1.19%. Market experts have set a consensus target price of $76.33, with ratings from BMO Capital, Mizuho, and Wells Fargo indicating a positive outlook. The next earnings report is due in 27 days.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 5:46 pm

MRK

The FDA approved Merck & Co Inc's Winrevair (sotatercept) for pulmonary arterial hypertension, expected to be a key catalyst for Merck's stock in 2024. Cantor Fitzgerald maintains an Overweight rating on MRK with a price target of $135, citing the drug's approval and potential sales impact. Merck's stock has outperformed the S&P 500 year-to-date, and the successful launch of sotatercept could lead to upward earnings revisions and stock multiple expansion. Approximately 40,000 U.S. patients could benefit from sotatercept, with Merck establishing a dedicated business unit for the drug.

Portfolio Pulse from Vandana Singh

March 27, 2024 | 5:38 pm